Neurology · DepressionRegulatory Approvalregulatorymid-term

FDA Accepts Supplemental Application for SPRAVATO (Esketamine)

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Janssen38 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/26/2026, 6:32:03 AM

Assessment confidence: 55% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for SPRAVATO is significant as it may lead to expanded indications or label changes, enhancing Janssen's competitive position in the depression treatment market. This development necessitates close monitoring of the approval process and potential impacts on market dynamics. Regulatory context from FDA (FDA AP — SPRAVATO (SUPPL)) supports the near-term read. Assessment grounded in 20 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on market share and competitive strategies in the depression space. The strongest clinical anchor is Characterization and Treatment of Adolescent Depression (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Depression, 5 regulatory and 3 competitive items passed relevance filtering for Janssen.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Approves Supplemental Application for INREBIC (Fedratinib Hydrochloride). This acceptance may enhance Janssen's position in the depression treatment market, potentially impacting competitors with similar offerings.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — SPRAVATO (SUPPL) (FDA). Entity match (janssen). Relevant agencies in corpus: FDA, PMDA. The acceptance of the supplemental application indicates a pathway for potential label updates, which could influence prescribing practices and market access.

Key Risks

Elevated medium regulatory exposure for Janssen could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, this could strengthen Janssen's market share in the depression space, potentially affecting revenue streams for competitors with similar products.
Upside for Janssen may improve if Evaluation of the Safety and Effectiveness of the CORUS™ Posterior Cervical Stabilization System 3D (PCSS 3D) for the Treatment of 2-level Cervical Degenerative Disease (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the implications of this approval on market share and competitive strategies in the depression space.

What Would Change This Assessment

This becomes more urgent if Monitor for the approval timeline and any subsequent label changes or indications that may arise from this application.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — SPRAVATO (SUPPL)
FDAhigh relevance
Entity match (janssen)
FDA document
View source
FDA AP — SPRAVATO (SUPPL)
FDAhigh relevance
Entity match (janssen)
FDA document
View source
[IBENTO][IBENTO]PMDA-ATC Blood Products Seminar 2026 for PPWG Applications open.
PMDAmedium relevance
Moderate corpus alignment
FDA document
View source
IND Application Reporting: IND Safety Reports
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Investigational New Drug (IND) Application
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Characterization and Treatment of Adolescent Depression
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Randomized, Controlled, Exploratory Study on the Treatment of Dental Implants Using the AmbiJet System for Peri-implantitis and Peri-implant Mucositis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Virtual Reality (VR) -Directed Brain Gut Behavioral Treatment (BGBT) for Inflammatory Bowel Disease (IBD) Inpatients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluation, Treatment and Monitoring of Patients With Known or Suspected Parasitic Infection
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluation of the Safety and Effectiveness of the CORUS™ Posterior Cervical Stabilization System 3D (PCSS 3D) for the Treatment of 2-level Cervical Degenerative Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves Supplemental Application for INREBIC (Fedratinib Hydrochloride)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for LEQEMBI Supplement Application
Humanexa Signalsmedium relevance
Moderate corpus alignment

A comprehensive review on Jiao-tai-wan: Traditional application, pharmacokinetics, and therapeutic mechanisms in multiple disorders.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Janssen
SPRAVATO
depression treatment market

Commercial impact

medium

If approved, this could strengthen Janssen's market share in the depression space, potentially affecting revenue streams for competitors with similar products.

Regulatory impact

medium

The acceptance of the supplemental application indicates a pathway for potential label updates, which could influence prescribing practices and market access.

What to watch

Monitor for the approval timeline and any subsequent label changes or indications that may arise from this application.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.